Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $1.97B
• Dividend Yield: N/A
• Average Volume (3M): 782.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.48
• Revenue Growth: -25.85%
• EPS Growth: -23.89%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 65,119,570
• 10 Day Avg. Volume: 646,464
• 30 Day Avg. Volume: 782,244
• PEG Ratio: 0.40
• Price to Book (P/B): 2.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.42
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 6.35
• Enterprise Value/Gross Profit: 48.37
• Enterprise Value/Ebitda: -2.82
• 1Y Price Target: $53.71
• Price Target Upside: 77.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15

Kymera Therapeutics shows a blend of strengths and challenges typical of a biotech firm. Strong equity and strategic pipeline advancements are offset by declining revenue and cash flow difficulties. Technical signals are mixed, and the valuation is unattractive due to negative earnings. The overall score reflects these mixed indicators, with positive guidance from the earnings call providing some optimism.

Positive Factors

Financial Strategy

Cash runway is updated to into 1H28 vs. mid-2027 previously, which extends runway past the KT-621 Ph 2b readouts.

Program Development

The new IRF5 program has potential to drive additional excitement for the stock over the longer term.

Strategic Decisions

Investors will likely welcome the discontinuation of the TYK2 program and associated burn given perceived crowding in the TYK2 landscape.

Negative Factors

Financial Performance

Kymera reported a Q1 net loss of $66MM.

Program Discontinuation

KT-295 (TYK2) will not be advanced in order to allocate resources elsewhere.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics (KYMR) is a biotechnology company specializing in the development of targeted protein degradation therapies. The company focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins, addressing unmet medical needs in areas such as oncology, inflammation, and immunology. Kymera's proprietary technology platform, Pegasus, enables the identification and development of these targeted protein degraders.

How the Company Makes Money

Kymera Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties on sales of products developed using their technology. Additionally, the company may also receive funding through research grants and government contracts to support the development of their therapeutic candidates. As Kymera advances its own pipeline of drug candidates, the commercialization of approved therapies would also become a significant source of revenue.

Kymera Therapeutics Financial Statement Overview

Summary

Kymera Therapeutics demonstrates typical characteristics of a biotech firm in a growth phase with declining revenue and high R&D costs leading to net losses. Despite a strong equity base and low leverage, the company faces cash flow management challenges.

Income Statement

Kymera Therapeutics has experienced declining revenue over the past year, with a notable drop of 40.1% from $78.59M to $47.07M. The company operates at a loss, as indicated by negative EBIT and net income, leading to negative margins. The gross profit margin remains high due to the absence of cost of goods sold, but the net profit margin is significantly negative, reflecting the company's high operating costs relative to its revenue.

Balance Sheet

The balance sheet shows strong equity relative to liabilities, with a debt-to-equity ratio of 0.10, indicating low leverage. However, the company's return on equity is negative due to its net losses. The equity ratio is healthy at 85.4%, suggesting stability in its asset financing structure, primarily through equity rather than debt.

Cash Flow

Operating cash flow is negative, reflecting cash outflow from operations. However, the company has managed free cash flow deficit through substantial financing activities. There is a significant increase in free cash flow deficit from the previous period, indicating potential cash management challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
47.07M	78.59M	46.83M	72.83M	34.03M
	Gross Profit
39.70M	-110.49M	43.85M	70.44M	-28.07M
	EBIT
-261.63M	-165.53M	-161.26M	-100.53M	-46.30M
	EBITDA
-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
	Net Income Common Stockholders
-223.86M	-146.96M	-151.83M	-98.00M	-43.95M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
488.74M	374.88M	559.49M	567.61M	458.73M
	Total Assets
978.03M	575.76M	603.13M	605.90M	487.18M
	Total Debt
87.76M	84.67M	17.34M	17.96M	17.99M
	Net Debt
-32.49M	-25.29M	-51.06M	-30.01M	-13.01M
	Total Liabilities
142.42M	180.79M	112.98M	146.27M	203.29M
	Stockholders Equity
835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow		Free Cash Flow
-207.34M	-137.31M	-155.92M	-130.54M	79.03M
	Operating Cash Flow
-194.50M	-102.83M	-153.09M	-128.95M	88.13M
	Investing Cash Flow
-404.08M	139.89M	20.52M	-99.83M	-422.59M
	Financing Cash Flow
608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 30.25
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Negative. The current price of 30.25 is below the 20-day moving average (MA) of 31.52, above the 50-day MA of 29.93, and below the 200-day MA of 40.03, indicating a neutral trend. The MACD of 0.28 indicates Positive momentum. The RSI at 49.37 is Neutral, neither overbought nor oversold. The STOCH value of 26.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	76 Outperform	$2.01B	13.37	24.71%	―	20.62%	14.08%
BCRX	55 Neutral	$2.14B	―	18.68%	―	41.67%	75.79%
KYMR	54 Neutral	$1.97B	―	-32.17%	―	-25.85%	-23.89%
AGIO	54 Neutral	$1.69B	2.59	60.26%	―	25.96%	―
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
BEAM	45 Neutral	$1.80B	―	-38.04%	―	-82.38%	-164.76%
IRON	43 Neutral	$1.67B	―	-23.34%	―	―	-14.19%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Introduces KT-579 Targeting IRF5

On May 9, 2025, Kymera Therapeutics announced the introduction of KT-579, an oral degrader targeting IRF5, with potential applications in rheumatic and autoimmune diseases, expected to enter Phase 1 trials in early 2026. The company also reported progress in its KT-621 and KT-474 programs, including a $20 million milestone payment from Sanofi for the IRAK4 collaboration, and a strategic decision to focus resources on the STAT6 and IRF5 programs, extending its financial runway into 2028.

Spark’s Take on KYMR Stock

According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.

Kymera Therapeutics’ strengths lie in its solid equity base, low leverage, and strategic partnerships, notably with Sanofi. However, significant revenue decline, high R&D costs, and cash flow challenges weigh on its financial performance. Technical analysis shows mixed signals with a potential downward trend, while the valuation remains unattractive due to negative earnings. The earnings call provides a positive outlook on clinical progress but highlights cost challenges and limited revenue diversification.

To see Spark’s full report on KYMR stock, click here.

Kymera Therapeutics Grants Performance Stock Units to Executives

On March 3, 2025, Kymera Therapeutics’ Board and Compensation Committee approved the grant of performance stock units (PSUs) to key employees, including executives, under the company’s 2020 Stock Option and Incentive Plan. These PSUs will vest in three installments based on achieving specific clinical milestones, potentially impacting employee incentives and aligning them with the company’s clinical development goals.